Sonnet Biotherapeutics, Inc.:
Sonnet is utilizing a platform approach to develop immuno-oncology therapeutics featuring a proprietary fully human “Albumin Binding Domain” (ABD) capable of linking 1-2 different therapeutic targets. Sonnet's interleukin-based candidate has been shown to enhance pK (up to 10 fold) and improve tumor delivery with an increase in in vivo efficacy (30 fold) as demonstrated in a mice tumor model. The Sonnet platform de-risks the use of interleukins by greatly extending their in vivo half-life, while also improving their specificity to tumor tissue.
Biotech Company /
100 Overlook Center, 2nd Floor
Princeton, NJ 08540
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.